Esther Conde, Susana Hernandez, Jose Luis Rodriguez Carrillo, Rebeca Martinez, Marta Alonso, Daniel Curto, Beatriz Jimenez, Alejandra Caminoa, Amparo Benito, Pilar Garrido, Sergi Clave, Edurne Arriola, Isabel Esteban-Rodriguez, Javier De Castro, Irene Sansano, Enriqueta Felip, Federico Rojo, Manuel Dómine, Ihab Abdulkader, Jorge Garcia-Gonzalez, Cristina Teixido, Noemi Reguart, Desamparados Compañ, Amelia Insa, Nuria Mancheño, Sarai Palanca, Oscar Juan-Vidal, Nuria Baixeras, Ernest Nadal, Maria Cebollero, Antonio Calles, Paloma Martin, Clara Salas, Mariano Provencio, Ignacio Aranda, Bartomeu Massuti, Laura Lopez-Vilaro, Margarita Majem, Luis Paz-Ares, Fernando Lopez-Rios
INTRODUCTION: RET inhibitors with impressive overall response rates are now available for patients with NSCLC, yet the identification of RET fusions remains a difficult challenge. Most guidelines encourage the upfront use of next-generation sequencing (NGS), or alternatively, fluorescence in situ hybridization (FISH) or reverse transcriptase-polymerase chain reaction (RT-PCR) when NGS is not possible or available. Taken together, the suboptimal performance of single-analyte assays to detect RET fusions, although consistent with the notion of encouraging universal NGS, is currently widening some of the clinical practice gaps in the implementation of predictive biomarkers in patients with advanced NSCLC...
April 2024: JTO clinical and research reports